Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHervé Avet‐LoiseauJCJill CorreLMLudovic Martinet

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing reveals immune landscape dynamics affecting minimal residual disease in myeloma, suggesting new biomarker pathways.

Key Points

  • This research seeks to understand the immune microenvironment's role in treatment responses in multiple myeloma patients.
  • Conducted single-cell RNA sequencing on CD45⁺ bone marrow immune cells from 85 NDMM patients
  • Analyzed changes before and after treatment with Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone
  • Correlated remodeling patterns with minimal residual disease status.
  • IsaKRD induction significantly reshaped the bone marrow immune landscape.
  • Notable reductions in B, NK, and T cells alongside expansions in inflammatory myeloid populations were observed.
  • Distinct immune signatures correlated with MRD status and treatment efficacy.

Cite This Study

Avet‐Loiseau et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d603https://doi.org/10.1182/blood-2025-3932
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial2026 · 3 citations
  2. 2Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion2025
  3. 3Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  4. 4Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma2026
  5. 5Abstract 6881: Investigating the role of post-transplant bone marrow immune dysregulation in multiple myeloma2024